CTOs on the Move

Delfi Diagnostics

www.delfidiagnostics.com

 
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Tobias Mann
 Vice President of Software Engineering and Information Technology Profile
Timothy McDaniel
 Vice President of Technology Development Profile

Funding

Delfi Diagnostics raised $100M on 01/12/2021

Similar Companies

InhibRx

Lyophilization Services of New England

Lyophilization Services of New England is a Bedford, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Noxilizer

Noxilizer, Inc. provides room-temperature nitrogen dioxide sterilization technology that offers many benefits over traditional sterilization methods. Noxilizer sells sterilization equipment to pharmaceutical, biotech and medical device manufacturers and also offers contract sterilization services at its Baltimore, MD facilities. Noxilizer’s expert microbiology and material compatibility team is ready to partner to solve sterilization challenges through every phase of the process. Noxilizer, Inc., founded in 2004, is privately held with offices in the US, United Kingdom, and Japan.

LifeServe Blood Center

LifeServe Blood Center is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmative

Pharmative is a Northridge, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.